Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Abstract

Authors

• Vinayak Muralidhar
  Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA.
• Meredith M Regan
  Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Lillian Werner
  Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Mari Nakabayashi
  Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Carolyn P Evan
  Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Joaquim Bellmunt
  Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Toni K Choueiri
  Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Aymen A Elfiky
  Dimitris Bertsimas, Jack Dunn, Colin Pawlowski, John Silberholz, Alexander Weinstein, and Ying Daisy Zhuo, Massachusetts Institute of Technology, Cambridge; Eddy Chen, Massachusetts General Hospital Cancer Center; Harvard Medical School; Aymen A. Elfiky, Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard Medical School, Boston, MA.
• Lauren C Harshman
  Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
• Rana R Mckay
  University of California San Diego, San Diego, CA, USA.
• Mark M Pomerantz
  Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
• Christopher J Sweeney
  Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
• Mary-Ellen Taplin
  Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Mary_Taplin@DFCI.harvard.edu.
• Philip W Kantoff
  Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• Paul L Nguyen
  Department of Radiation Oncology, Dana-Farber/Brigham Cancer Center, Boston.

Keywords

External Resources